Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186940 · ClinicalTrials.gov registry record
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A clinical trial, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- 16
- Enrollment target
NCT00186940 is a clinical trial that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 16 participants.
The verdict
NCT00186940 has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.
Interventions
- DRUG Rasburicase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186940
The ClinicalTrials.gov registry entry for NCT00186940 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rasburicase is the first listed.
NCT00186940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186940 about?
NCT00186940 is a clinical study titled "Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients". This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.
What is the current status of trial NCT00186940?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2005-03. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00186940?
The interventions under investigation include: Rasburicase (DRUG).
Who is sponsoring clinical trial NCT00186940?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.